Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04892017 · ClinicalTrials.gov registry record · Phase 1

A Phase 1/2 Study of Inlexisertib (DCC-3116) in Patients With RAS/MAPK Pathway Mutant Solid Tumors

A Phase 1 study of Non-Small Cell Lung Cancer and Advanced Solid Tumor, sponsored by Deciphera Pharmaceuticals.

Active
Registry status
Phase 1
Development phase
144
Enrollment target
10
Study locations

NCT04892017 is a Phase 1 study of Non-Small Cell Lung Cancer and Advanced Solid Tumor that is active but no longer recruiting, run by Deciphera Pharmaceuticals. The registered enrollment target is 144 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (78% lower). The trial reports 10 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04892017, a Phase 1 study of Non-Small Cell Lung Cancer and Advanced Solid Tumor, is active but no longer recruiting, sponsored by Deciphera Pharmaceuticals.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
144 participants
Enrollment target
10
Study locations

Study Summary

This is a Phase 1/2, multicenter, open label, first in human (FIH) study of inlexisertib as monotherapy, and in combination with trametinib, binimetinib, or sotorasib in patients with advanced or metastatic solid tumors with RAS/MAPK pathway mutation. The study consists of 2 parts, a dose-escalation phase, and an expansion phase.

Conditions Studied

Non-Small Cell Lung Cancer Advanced Solid Tumor Metastatic Solid Tumor

Interventions

  • DRUG Trametinib
  • DRUG Sotorasib
  • DRUG Binimetinib
  • DRUG Inlexisertib

Study Locations (10)

Texas

  • NEXT Oncology - Austin
  • The University of Texas MD Anderson Cancer Center - Houston
  • NEXT Oncology - San Antonio

Massachusetts

  • Massachusetts General Hospital - Boston

Missouri

  • Washington University Siteman Cancer Center - St Louis

New Jersey

  • Rutgers Cancer Institute - New Brunswick

New York

  • Laura & Isaac Perlmutter Cancer Center at NYU Langone Health - New York

Oregon

  • Oregon Health and Science University - Portland

Pennsylvania

  • Hospital of the University of Pennsylvania - Philadelphia

Wisconsin

  • University of Wisconsin Clinical Science Center - Madison

Trial Details

FieldValue
Enrollment Target 144 participants
Start Date 2021-06-15
Est. Completion 2028-08
Phase Phase 1

Sponsor

Deciphera Pharmaceuticals

21 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04892017

The ClinicalTrials.gov registry entry for NCT04892017 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 144 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (78% lower). The listed sponsor is Deciphera Pharmaceuticals, which has 21 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 4 interventions - of which Trametinib is the first listed.

NCT04892017 reports 10 study locations spanning 8 distinct geographic areas - top geographies include Texas, Massachusetts, Missouri.

Frequently Asked Questions

What is clinical trial NCT04892017 about?

NCT04892017 is a clinical study titled "A Phase 1/2 Study of Inlexisertib (DCC-3116) in Patients With RAS/MAPK Pathway Mutant Solid Tumors". This is a Phase 1/2, multicenter, open label, first in human (FIH) study of inlexisertib as monotherapy, and in combination with trametinib, binimetinib, or sotorasib in patients with advanced or metastatic solid tumors with RAS/MAPK pathway mutation. The study consists of 2 parts, a dose-escalation...

What is the current status of trial NCT04892017?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 144 participants. The study started on 2021-06-15. Estimated completion is 2028-08.

What conditions does trial NCT04892017 study?

This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Solid Tumor.

What interventions are being tested in trial NCT04892017?

The interventions under investigation include: Trametinib (DRUG), Sotorasib (DRUG), Binimetinib (DRUG), Inlexisertib (DRUG).

Who is sponsoring clinical trial NCT04892017?

This trial is sponsored by Deciphera Pharmaceuticals, which has 21 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04892017 being conducted?

This trial has 10 study locations across Massachusetts, Missouri, New Jersey, New York, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Non-Small Cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Non-Small Cell Lung Cancer

All registered trials for this condition

Advanced Solid Tumor

All registered trials for this condition

Massachusetts

All trials with a study site in Massachusetts

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.